First Bank & Trust Has $296,000 Stake in Zoetis Inc. $ZTS

First Bank & Trust trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 70.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,356 shares of the company’s stock after selling 5,537 shares during the quarter. First Bank & Trust’s holdings in Zoetis were worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC increased its stake in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Board of the Pension Protection Fund purchased a new position in shares of Zoetis during the 4th quarter valued at $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $116.62 on Friday. The firm has a market cap of $49.23 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.78 and a beta of 0.95. The company’s fifty day moving average is $123.62 and its 200-day moving average is $129.58. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12 month low of $113.30 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is currently 35.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZTS shares. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Finally, The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.